Nomogram for PSA Control in Prostate Cancer Treatment
Author Information
Author(s): Parker C C, Norman A R, Huddart R A, Horwich A, Dearnaley D P
Primary Institution: The Royal Marsden NHS Trust and Institute of Cancer Research
Hypothesis
Can a nomogram be developed to predict PSA control for patients undergoing neoadjuvant androgen deprivation and radical radiotherapy for localized prostate cancer?
Conclusion
The study developed a nomogram that effectively predicts PSA failure-free survival based on pre-treatment factors.
Supporting Evidence
- 233 out of 517 men developed PSA failure at a median follow-up of 44 months.
- The nomogram predicts freedom from PSA failure based on clinical T stage, grade, and presenting PSA.
- 5-year freedom from PSA failure rates varied significantly based on nomogram scores.
Takeaway
Doctors created a special chart to help predict how well treatment will work for men with prostate cancer who get hormone therapy and radiation.
Methodology
The study involved 517 men treated with neoadjuvant androgen deprivation and radical radiotherapy, with multivariate analysis performed to develop a nomogram for predicting PSA failure.
Potential Biases
Potential biases may arise from the historical treatment protocols and the lack of re-evaluation of earlier grading systems.
Limitations
The study's definition of PSA failure was constrained by the sensitivity of assays used, and it primarily included men with clinically detected prostate cancer rather than screen-detected cases.
Participant Demographics
Men with clinically localized prostate cancer, treated between 1988 and 1998, with a median presenting PSA of 20 ng/ml.
Statistical Information
P-Value
0.001
Confidence Interval
±3.6% to ±5.8%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website